What the FDA labels say about taking them together
Disopyramide and sotalol
Sotalol's FDA label of December 16, 2024 names disopyramide in its drug interactions section; the disopyramide label PlainMeds reads does not name sotalol. The sotalol label: “Class Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy with Betapace/Betapace AF, because of …”
Check it at the source: the disopyramide FDA label on DailyMed (effective August 24, 2026, Pfizer Laboratories Div Pfizer Inc); the sotalol FDA label on DailyMed (effective December 16, 2024, Legacy Pharma USA, Inc.).
What does the disopyramide label say about sotalol?
Disopyramide's label (effective August 24, 2026) does not name sotalol in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Norpace), Pfizer Laboratories Div Pfizer Inc, effective August 24, 2026 (SPL set e2aa1642-d262-4520-bc6a-9fd3ad795677), via openFDA; the full label on DailyMed
What does the sotalol label say about disopyramide?
Sotalol label, drug interactionsClass Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy with Betapace/Betapace AF, because of their potential to prolong refractoriness [see Warnings and Precautions ( 5.2 )].
Sotalol Hydrochloride label (ALTATHERA Pharmaceuticals, LLC, July 31, 2025), drug interactionsClass Ia antiarrhythmic drugs, such as disopyramide, quinidine, and procainamide, and other Class III drugs (for example, amiodarone) are not recommended as concomitant therapy, because of their potential for additive QTc prolongation [see Warnings and Precautions ( 5.1 )].
Source: FDA drug label (Sotalol Hydrochloride, NDA022306), ALTATHERA Pharmaceuticals, LLC, effective July 31, 2025 (SPL set ff3061ab-d930-4318-a5be-684e38be229e), via openFDA
Source: FDA drug label (Sotylize, NDA205108), Azurity Pharmaceuticals, Inc., effective January 24, 2024 (SPL set 1f33f900-0777-4a92-a7f7-00cf3d57d95c), via openFDA
Source: FDA drug label (BETAPACE), Legacy Pharma USA, Inc., effective December 16, 2024 (SPL set a6a7702f-36c9-45db-b640-453dc324baee), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Disopyramide | Sotalol | |
|---|---|---|
| Labeled for | n/a | Atrial fibrillation |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.801 per capsule 100 mg capsule | $0.0707 per tablet 80 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once